Zymeworks
Zymeworks

Zymeworks

Biotechnology
WebsiteInvestor RelationsSEC
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

$1.8B

Market Cap • 10/2/2026

2003

(23 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Canada

Canada

Country

Valuation

P/B

31,5

P/S

50,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,8

EPS

—

Market Cap

Market Cap

1,8B

EV

1,6B

EV/Revenue

45,3

EV/EBITDA

-11,7

EV/EBIT

-11,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

7,6%

Total Yield

7,6%

Payout

0%

Retained Earnings

-824,4M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

337,1%

Capex/Revenue

3,4%

Capex/D&A

24,6%

Capex/OCF

-1%

SBC/OCF

—

% PPE

6,8%

% Goodwill

3%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

11,5%

CAGR Op. Income 5Y

-8,7%

CAGR Net Income 5Y

-9,3%

CAGR EPS 5Y

-14,2%

CAGR OCF 5Y

-5,1%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

6,3

Quick Ratio

5,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium